Journal
SUPPORTIVE CARE IN CANCER
Volume 30, Issue 8, Pages 7031-7038Publisher
SPRINGER
DOI: 10.1007/s00520-022-07126-y
Keywords
Acute myeloid leukemia; Venetoclax; Neutropenia; Infectious complication; Mortality
Funding
- Medical Health Science and Technology Project of Zhejiang Provincial Health Commission [2017KY059]
Ask authors/readers for more resources
The study aimed to investigate the incidence, sites, main pathogens, and risk factors for infectious complications in adult acute myeloid leukemia (AML) patients receiving venetoclax combined with decitabine or azacitidine. The results showed that compared to conventional chemotherapy, venetoclax combined with decitabine or azacitidine significantly reduced the incidence of infectious complications. High leukemia burden and fever were identified as independent risk factors for infections.
Purpose The purpose of this study was to identify the incidence, sites and main pathogens, and risk factors for infectious complications occurring in patients with adult acute myeloid leukemia (AML) during the first course of venetoclax combined with decitabine or azacitidine. Methods A retrospective cohort analysis was performed of 81 patients with AML older than 14 years who received the first cycle of venetoclax combined with a hypomethylating agent (HMA) between March 2018 and March 2021 at our institution. Infectious complications, if any, were documented. Results Among a total of 81 cases of AML, 59 (72.8%) patients occurred infections, including fever without an identifiable source (28.8%), clinically documented infections (40.7%), and microbiologically documented infections (30.5%). The most commonly isolated organism in culture was Candida albicans, followed by Klebsiella pneumonia, and Pseudomonas aeruginosa. The 4-week and 8-week mortality rates were 3.7% and 7.4%, respectively. In multivariate analysis, a high proportion of blasts in bone marrow, decreased hemoglobin level, and fever with or without a documented infection at baseline were significant independent risk factors for infectious complications. Conclusion Compared with conventional chemotherapy, the incidence of infectious complications of venetoclax combined with decitabine or azacitidine significantly decreased. Pretreatment high leukemia burden and fever were independent risk factors for infections.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available